ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed a strategic partnership with Georgia Eye Associates, expanding its presence into the Lawrenceville and northeast Atlanta regions. Eye…
Global Retinal Implant Market Size, Share & Trends Analysis Report by Device Type (Retina Implant Alpha AMS, Implantable Miniature Telescope, and Argus II) and Region (2018-2026) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinal Implant Market Size, Share & Trends Analysis Report By Device Type (Retina Implant Alpha AMS, Implantable Miniature Telescope, and Argus II), By Region, And Segment Forecasts, 2018 – 2026” report has been added to …
Uncategorized
OSN’s top news of the week
Here are the top stories of the past week on Healio.com/OSN: Dexycu receives permanent J-codeDexycu (dexamethasone intraocular suspension) 9%, the first FDA-approved, single-dose, sustained-release intracameral steroid for the treatment of postoperativ…
Uncategorized
Read OSN’s Nov. 25 publication exclusives online
The cover story in the Nov. 25, 2018, issue of Ocular Surgery News focuses on identifying and preventing embezzlement in ophthalmology practices. Here are some of the issue’s publication exclusives: Cover storyMedical practices take steps to prevent em…
Tackling Alzheimer’s Biomarkers Using Machine Learning: Interview with IQuity CEO, Dr. Chase Spurlock
Losing one’s memories, and therefore one’s identity, must be a terrifying experience. With a global estimate of almost 50 million people living with dementia, predicted to rise to more than 130 million by 2050, the burden of Alzheimer’s and dementia are indisputable. While there are still no approved drugs for the treatment of Alz (Read more...)
Uncategorized
Half-dose PDT resolves subretinal fluid in chronic central serous chorioretinopathy
Half-dose photodynamic therapy for the treatment of chronic central serous chorioretinopathy had superior results when compared with high-density subthreshold micropulse laser treatments.The PLACE trial, an open-label, multicenter, randomized controlle…